Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Safety of Neoadjuvant Immunotherapy in Resectable Cancers: A Meta-Analysis.Frontiers in immunology · 2022
   Pooled it
2. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.Annals of surgical oncology · 2024
   Trial
3. The intratumoral landscape of T cell receptor repertoire in esophageal squamous cell carcinoma.Journal of translational medicine · 2024
   Article
4. Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas.Journal of translational medicine · 2023
   Article
5. Metabolomics unveils the mechanism of Bufei Huayu decoction in combination with cisplatin against non-small cell lung cancer (NSCLC).Heliyon · 2023
   Article
6. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.Frontiers in immunology · 2023
   Review
7. Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas.Frontiers in immunology · 2023
   Review
8. Photodynamic Opening of the Blood-Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors.Pharmaceutics · 2022
   Review
9. Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma.BMC gastroenterology · 2022
   Article
10. NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens.Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
11. Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.Frontiers in oncology · 2022
    Review
12. Progress in advanced nanotherapeutics for enhanced photodynamic immunotherapy of tumor.Theranostics · 2022
    Review
13. Ensemble deep learning enhanced with self-attention for predicting immunotherapeutic responses to cancers.Frontiers in immunology · 2022
    Article
14. Incidence, clinicopathologic, and genetic characteristics of mismatch repair gene-mutated glioblastomas.Journal of neuro-oncology · 2021
    Article
15. Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study.Translational lung cancer research · 2021
    Article
16. Bronchopleural fistula following a video-assisted thoracoscopic surgery lobectomy after neoadjuvant therapy of pembrolizumab: a case report and literature review.Annals of translational medicine · 2020
    Article
17. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.Human molecular genetics · 2020
    Review
18. Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis.Oncoimmunology · 2020
    Article
19. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cellular & molecular immunology · 2020
    Review
20. The efficiency ofEuropean journal of nuclear medicine and molecular imaging · 2020
    Article

Corrections and comments

• Commented on by
  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.2018
• Comment on
  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.2018

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as